Clotting markers in Cardiac Electrophysiological Procedures

• Research type

  Research Study

• Full title

  The Effect of Electrophysiological Procedures on Markers of Thrombosis in the Systemic and Local Circulation

• IRAS ID

  228022

• Contact name

  Muzahir Tayebjee

• Contact email

  muzahir.tayebjee@nhs.net

• Sponsor organisation

  Leeds Teaching Hospitals NHS Trust

• Duration of Study in the UK

  1 years, 0 months, 27 days

• Research summary

  Invasive treatment of cardiac arrhythmias is common practice. There are a number of techniques and procedures in use. These treatments can damage access sites in the veins and the heart, and may lead to the activation of inflammatory and blood clotting systems. Although the prevalence of thromboembolic complications is relatively low, there is currently no way to determine risk factors for such events. Analysis of markers of clotting and inflammation may prove invaluable in determining the effects of these invasive procedures, during which samples can be taken from various sites of the circulatory system, including chambers of the heart. This would allow insight in to the changes in the local and systemic environments. Data from the study will be useful to evaluate the alterations in inflammation and blood clotting during electrophysiological procedures. This will improve our understanding of thrombotic risk and may play a role in prevention of thromboembolic complications.
  Patients referred for interventional electrophysiological procedures, including catheter ablation, for treatment of atrial fibrillation, supraventricular tachycardia or ventricular tachycardia will be considered for the study. Patients undergoing radiofrequency ablation will be excluded. Baseline demographics will be collected, including cardiovascular risk factor, and prior cardiac investigations will be performed. Details of the procedure will also be given to the patient. The study involves taking an extra blood sample 30-40 ml during the interventional procedure. Approximately 5 mL “clean”, undiluted blood will be drawn (per site) and will be taken to the laboratory at Leeds Institute of Cardiovascular and Metabolic Medicine. Assessment of clot formation will be performed, and plasma samples will be prepared for storage for future use in assays to measure changes in biomarkers of inflammation and clotting.

• REC name

  North of Scotland Research Ethics Committee 2

• REC reference

  20/NS/0003

• Date of REC Opinion

  13 Jan 2020

• REC opinion

  Favourable Opinion